Literature DB >> 10698493

Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene.

L Glukhova1, C Lavialle, D Fauvet, I Chudoba, G Danglot, E Angevin, A Bernheim, A F Goguel.   

Abstract

Molecular cytogenetic analysis of several sporadic papillary renal cell carcinomas and of their xenografts in immunodeficient mice had previously allowed us to delimit a minimal overrepresented region of chromosome 7 shared by all of them to band 7q31. We have refined the location of the overlapping region to the junction of the subbands 7q31.2 and 7q31.3 by reverse painting with two differently labelled probes prepared from the small chromosome 7 derivatives microdissected from the cells of two distinct tumours. This small region was shown to contain the MET proto-oncogene, present at three to four copies per cell as determined by Southern blot analysis. The increased copy number of the MET gene was found to be associated with its overexpression at the mRNA level. However, no change in MET copy number or expression level was observed in the cells from two xenografted tumours serially transplanted into immunodeficient mice, as compared to those from the corresponding initial tumours. Our results indicate that expression of the MET proto-oncogene above a critical threshold is required for the maintenance of the tumorigenic phenotype of at least some papillary renal cell carcinomas, but does not further increase during tumour progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698493     DOI: 10.1038/sj.onc.1203397

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.

Authors:  Brendan D Looyenga; Kyle A Furge; Karl J Dykema; Julie Koeman; Pamela J Swiatek; Thomas J Giordano; Andrew B West; James H Resau; Bin T Teh; Jeffrey P MacKeigan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

2.  Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.

Authors:  Beatriz A Walter; Maria Begnami; Vladimir A Valera; Mariarita Santi; Elisabeth J Rushing; Martha Quezado
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

3.  Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases.

Authors:  M Udart; J Utikal; G M Krähn; R U Peter
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

4.  MET expression in sporadic renal cell carcinomas.

Authors:  Jong Sun Choi; Mi-Kyung Kim; Jin Won Seo; Yoon-La Choi; Dong Hoon Kim; Yi Kyeong Chun; Young Hyeh Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

5.  Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists.

Authors:  Darwin L Lim; Raymond Ko; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 6.  Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review).

Authors:  Nidhi Jariwala; Devaraja Rajasekaran; Jyoti Srivastava; Rachel Gredler; Maaged A Akiel; Chadia L Robertson; Luni Emdad; Paul B Fisher; Devanand Sarkar
Journal:  Int J Oncol       Date:  2014-11-18       Impact factor: 5.650

7.  Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.

Authors:  Michal Kovac; Carolina Navas; Stuart Horswell; Max Salm; Chiara Bardella; Andrew Rowan; Mark Stares; Francesc Castro-Giner; Rosalie Fisher; Elza C de Bruin; Monika Kovacova; Maggie Gorman; Seiko Makino; Jennet Williams; Emma Jaeger; Angela Jones; Kimberley Howarth; James Larkin; Lisa Pickering; Martin Gore; David L Nicol; Steven Hazell; Gordon Stamp; Tim O'Brien; Ben Challacombe; Nik Matthews; Benjamin Phillimore; Sharmin Begum; Adam Rabinowitz; Ignacio Varela; Ashish Chandra; Catherine Horsfield; Alexander Polson; Maxine Tran; Rupesh Bhatt; Luigi Terracciano; Serenella Eppenberger-Castori; Andrew Protheroe; Eamonn Maher; Mona El Bahrawy; Stewart Fleming; Peter Ratcliffe; Karl Heinimann; Charles Swanton; Ian Tomlinson
Journal:  Nat Commun       Date:  2015-03-19       Impact factor: 14.919

Review 8.  Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.

Authors:  Philippe Rochigneux; Jeanne Thomassin-Piana; Sophy Laibe; Serge Brunelle; Naji Salem; Bernard Escudier; Gilles Vassal; Gwenaelle Gravis
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

9.  MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases.

Authors:  Shirong Ma; Linni Fan; Yixiong Liu; Yingmei Wang; Kangjie Yu; Lifeng Wang; Na Fang; Fang Liu; Shuangping Guo; Zhe Wang
Journal:  Diagn Pathol       Date:  2018-08-21       Impact factor: 2.644

10.  Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer.

Authors:  Lucheng Zhu; Jiafeng Liang; Bing Xia; Yasi Xu; Ziliang Qian; Shenglin Ma; Shirong Zhang
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.